UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
Quarterly Report Under Section 13 or 15(d) of
The Securities Exchange Act of 1934
For quarter ended: June 30, 1997 Commission File No. 1-12575
UTAH MEDICAL PRODUCTS, INC.
(Exact name of Registrant as specified in its charter)
UTAH 87-0342734
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
7043 South 300 West
Midvale, Utah 84047
Address of principal executive offices
Registrant's telephone number: (801) 566-1200
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and; (2) has been subject to such
filing requirements for the past 90 days. Yes X No
The number of shares outstanding of the registrant's common stock as of August
13, 1997: 8,388,786
UTAH MEDICAL PRODUCTS, INC.
INDEX TO FORM 10-Q
PART I - FINANCIAL INFORMATION PAGE
Item 1. Financial Statements
Balance Sheets as of June 30, 1997
and December 31, 1996 1
Statements of Operations for the three and six months
ended June 30, 1997 and June 30, 1996 2
Statements of Cash Flows for the six months ended
June 30, 1997 and June 30, 1996 3
Notes to Financial Statements 4
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations 6
PART II - OTHER INFORMATION
Item 4. Submission of Matters to a vote of Security Holders 10
Item 6. Exhibits and Reports on Form 8-K 10
SIGNATURES 10
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
UTAH MEDICAL PRODUCTS, INC.
BALANCE SHEETS AS OF JUNE 30, 1997 AND
DECEMBER 31, 1996
(unaudited)
ASSETS
CURRENT ASSETS: JUNE 30, 1997 DECEMBER 31, 1996
------------- -----------------
Cash $2,439,956 $3,038,956
Investments 165,000 1,458,543
Accounts receivable - net 3,091,914 3,804,857
Other receivables 712,942 1,205,985
Inventories 6,389,444 4,750,442
Prepaid expenses 173,134 91,273
Deferred income taxes 587,242 595,639
------------- -------------
Total current assets 13,559,632 14,945,695
PROPERTY AND EQUIPMENT - NET 13,170,250 13,367,597
INTANGIBLE ASSETS - NET 900,757 602,393
------------- -------------
TOTAL $27,630,639 $28,915,685
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 1,684,560 $ 1,885,743
Accrued expenses:
Payroll and payroll taxes 588,227 1,132,309
Reserve for litigation expenses 740,204 649,840
Income taxes payable
Other 288,745 271,947
Revolving line of credit 2,150,000
Deferred revenue 85,600 135,600
------------- -------------
Total current liabilities 5,537,336 4,075,439
DEFERRED REVENUE 44,634 87,492
DEFERRED INCOME TAXES 464,761 369,759
------------- -------------
Total liabilities 6,046,731 4,532,690
------------- -------------
STOCKHOLDERS' EQUITY:
Preferred stock - $.01 par value; authorized
- 5,000,000 shares; no shares issued or
outstanding
Common stock - $.01 par value; authorized -
50,000,000 shares; issued - June 30, 1997,
8,388,786 shares December 31, 1996,
8,785,736 shares 83,888 87,857
Unrealized gain on investments
available-for-sale, net of tax 21,942 58,494
Cumulative foreign currency translation
adjustment (349,914) 217,444
Retained earnings 21,827,992 24,019,200
------------- -------------
Total stockholders' equity 21,583,908 24,382,995
------------- -------------
TOTAL $27,630,639 $28,915,685
============= =============
see notes to financial statements
UTAH MEDICAL PRODUCTS, INC.
STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS
ENDED JUNE 30, 1997 AND JUNE 30, 1996
(unaudited)
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
-------------------------- --------------------------
1997 1996 1997 1996
------------- ------------ ------------ ------------
NET SALES $ 5,100,577 $10,089,176 $10,273,971 $20,056,766
COST OF SALES 2,429,370 5,083,949 4,895,164 10,456,480
------------- ------------ ------------ ------------
GROSS MARGIN 2,671,207 5,005,227 5,378,807 9,600,286
------------- ------------ ------------ ------------
EXPENSES:
Selling, general and administrative 1,334,546 1,521,835 2,711,684 2,970,181
Research & development 253,563 378,540 491,501 737,415
------------- ------------ ------------ ------------
Total 1,588,109 1,900,375 3,203,185 3,707,596
INCOME FROM OPERATIONS 1,083,098 3,104,852 2,175,622 5,892,690
OTHER INCOME 293,500 245,235 821,901 1,343,993
------------- ------------ ------------ ------------
INCOME BEFORE INCOME TAX EXPENSE 1,376,598 3,350,087 2,997,523 7,236,683
INCOME TAX EXPENSE 481,213 1,179,231 1,062,153 2,582,292
------------- ------------ ------------ ------------
NET INCOME $895,385 $2,170,856 $1,935,370 $4,654,391
============= ============ ============ ============
EARNINGS PER COMMON AND
COMMON EQUIVALENT SHARE $ 0.11 $ 0.23 $ 0.22 $ 0.47
============= ============ ============ ============
EARNINGS PER COMMON SHARE
ASSUMING FULL DILUTION $ 0.11 $ 0.23 $ 0.22 $ 0.47
============= ============ ============ ============
WEIGHTED AVERAGE NUMBER OF COMMON
AND COMMON EQUIVALENT SHARES 8,504,429 9,559,673 8,612,269 9,802,124
============= ============ ============ ============
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES ASSUMING FULL DILUTION 8,504,429 9,559,673 8,612,269 9,802,124
============= ============ ============ ============
see notes to financial statements
UTAH MEDICAL PRODUCTS, INC.
STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 1997 AND JUNE 30, 1996
(unaudited)
JUNE 30,
----------------------------
1997 1996
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $1,935,370 $4,654,391
----------- -----------
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization 620,078 671,876
Provision for (recovery of) losses on
accounts receivable (18,716) 17,574
(Gain)/Loss on disposal of assets (49,834) 370,576
Deferred income taxes 125,517 44,349
Tax benefit attributable to exercise and
disposition of incentive stock options
and stock purchase rights 16,359 70,887
Changes in operating assets and liabilities:
Accounts receivable - trade 731,660 537,059
Accrued interest and other receivables 493,044 59,303
Inventories (1,639,003) (730,176)
Prepaid expenses (81,861) 77,886
Accounts payable (201,184) (426,838)
Accrued expenses (436,919) (99,091)
Deferred revenue (92,858) 57,142
----------- -----------
Total adjustments (533,718) 650,547
----------- -----------
Net cash provided by operating activities 1,401,652 5,304,938
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
Property and equipment (902,469) (3,357,540)
Intangible assets (327,622) (258,039)
Purchases of investments (112,200) (3,315,186)
Proceeds from sale of:
Investments 1,401,001 9,802,283
Property and equipment 3,500 21,750
----------- -----------
Net cash provided by (used in) investing
activities 62,209 2,893,268
----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock 108,812 171,813
Common stock purchased and retired (4,321,673) (10,981,386)
Proceeds from issuance of short-term debt 2,150,000 0
----------- -----------
Net cash used in financing activities (2,062,861) (10,809,573)
----------- -----------
NET INCREASE (DECREASE) IN CASH (599,000) (2,611,367)
CASH AT BEGINNING OF PERIOD 3,038,956 5,064,913
----------- -----------
CASH AT END OF PERIOD $2,439,956 $2,453,546
=========== ===========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for:
Income taxes $1,155,710 $2,643,631
see notes to financial statements
UTAH MEDICAL PRODUCTS, INC.
NOTES TO FINANCIAL STATEMENTS
(unaudited)
(1) The unaudited financial statements presented herein have been prepared in
accordance with the instructions to form 10-Q and do not include all of the
information and note disclosures required by generally accepted accounting
principles. These statements should be read in conjunction with the financial
statements and notes thereto included in the Utah Medical Products, Inc. ("UM"
or "the Company") annual report on form 10-K for the year ended December 31,
1996. The accompanying financial statements have not been examined by
independent accountants in accordance with generally accepted auditing
standards, but in the opinion of management such financial statements include
all adjustments (consisting only of normal recurring adjustments) necessary to
summarize fairly the Company's financial position and results of operations.
The results of operations for the three and six months ended June 30, 1997 may
not be indicative of the results that may be expected for the year ending
December 31, 1997.
(2) Inventories at June 30, 1997 and December 31, 1996 consisted of the
following:
June 30, December 31,
1997 1996
------------ ------------
Finished goods $ 1,383,827 $ 1,000,438
Work-in-process 1,230,539 1,010,086
Raw materials 3,775,078 2,739,918
------------ ------------
Total $ 6,389,444 $ 4,750,442
============ ============
(3) The Company has adopted the disclosure-only provisions of Statement of
Financial Accounting Standards (SFAS) No. 123, Accounting for Stock-Based
Compensation. Accordingly, no compensation cost has been recognized in the
financial statements.
(4) In February 1997, the Financial Accounting Standards Board issued SFAS No.
128, Earnings per Share. This standard establishes standards for computing
earnings per share ("EPS"). SFAS No. 128 simplifies the approach for computing
EPS previously found in APB Opinion No. 15. It replaces the presentation of
primary EPS with a presentation of basic EPS. It also requires dual
presentation of basic and diluted EPS on the face of the income statement for
all entities with complex capital structures. SFAS No. 128 is effective for
financial statements issued for periods ending after December 15, 1997,
including interim periods. Early adoption is not permitted. The computation of
basic EPS under SFAS No. 128 would not have changed the net income amounts for
the three and six months ended June 30, 1997 and 1996 herein reported. Diluted
EPS for the six months ended June 30,1997 and for the three and six months ended
June 30, 1996 also would have been the same as herein reported. However, the
computation of diluted EPS would have changed the net income amounts for the
three months ended June 30, 1997 to $.10 per share from the $.11 reported
herein.
(5) Forward-Looking Information
This report contains certain forward-looking statements and information
relating to the Company that are based on the beliefs of management as well as
assumptions made by, and information currently available to, management. When
used in this document, the words "anticipate," "believe," "should," "project,"
"estimate," "expect," "intend" and similar expressions, as they relate to the
Company or its management, are intended to identify forward-looking statements.
Such statements reflect the current view of the Company respecting future events
and are subject to certain risks, uncertainties, and assumptions, including the
risks and uncertainties noted throughout the document. Although the Company has
attempted to identify important factors that could cause the actual results to
differ materially, there may be other factors that cause the forward statement
not to come true as anticipated, believed, projected, expected, or intended.
Should one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results may differ materially
from those described herein as anticipated, believed, projected, estimated,
expected, or intended.
General risk factors that may impact the Company's revenues include the
market acceptance of competitive products, obsolescence caused by new
technologies, the possible introduction by competitors of new products that
claim to have many of the advantages of UM's products at lower prices, the
timing and market acceptance of UM's own new product introductions, UM's ability
to efficiently manufacture its products, including the reliability of suppliers,
success in gaining access to important global distribution channels, marketing
success of UM's distribution and sales partners, budgetary constraints, the
timing of regulatory approvals for newly introduced products, and third party
reimbursement.
Risk factors, in addition to the risks outlined in the previous paragraph
that may impact the Company's assets and liabilities, as well as cash flows,
include risks inherent to companies manufacturing products used in health care
including claims resulting from the improper use of devices and other product
liability claims, defense of the Company's intellectual property, productive use
of assets in generating revenues, management of working capital including
inventory levels required to meet delivery commitments at a minimum cost, and
timely collection of accounts receivable.
Additional risk factors that may affect non-operating income include the
continuing viability of the Company's technology license agreements, actual cash
and investment balances, asset dispositions, and acquisition activities that may
require external funding.
(6) Subsequent Events
On July 20, 1997, UM purchased all of the common shares of
Columbia Medical & Surgical, Inc. (CMI), a privately held corporation located in
Redmond, Oregon. The purchase price was approximately $8.1 million, including
consideration for patent rights and non-competition agreements, paid in cash to
Columbia's two prior owners, Larry and Emily Smith. The acquisition will be
considered a purchase for accounting purposes. A $10,000,000 unsecured
revolving promissory note with First Security Bank, along with the Company's own
cash, were used for the purchase.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Results of Operations
Because of the relatively short span of time, results for any given three
or six month period in comparison with a previous three or six month period may
not be indicative of comparative results for the year as a whole.
a) Overview
Second quarter (2Q) 1997 financial results were down compared to 2Q 1996,
but about the same as in first quarter (1Q) 1997. Sales suffered in comparison
to the prior year because of the permanent decline in sales of disposable
pressure transducers to Baxter, a one-time buy-back of inventory from a
terminated distributor, and lower Intran(R) sales due to competition from two
manufacturers which UM believes are infringing its patents. In making a
strategic decision to convert, over the past five years, its Ob/Gyn sales
resources in the U.S. from third party distributors to its own employed direct
representatives, UM knew it could result in some short term loss of sales, but
determined it would ultimately benefit the Company due to better representation
of products, higher unit prices and higher sales volumes. Despite sales which
declined by 49%, gross profit margins improved to 52.4% of sales as compared to
49.6% of sales in 2Q 1996. Operating profit margins were hurt because of the
lower sales volume, which caused operating expenses to increase from 19% of
sales in 2Q 1996 to 31% of sales in 2Q 1997, despite the fact that actual
operating expenses in 2Q 1997 were about $300,000 lower than in 2Q 1996.
b) Revenues
UM divides revenues into three product-line categories: 1) critical care,
which is comprised primarily of components used in invasive blood pressure
monitoring, but also includes components for other types of pressure
monitoring, as well as disposable respiratory products used in hospitals; 2)
obstetrics, which is comprised mainly of devices for monitoring intrauterine
pressure during labor and delivery, although to a lesser extent electrodes for
fetal heart rate monitoring as well as other labor and delivery supplies, and a
product which unifies and improves clinician safety in the multiple step
procedure of clamping, cutting, and drawing blood samples from the umbilical
cord immediately following childbirth; and 3) gynecology, which comprises an
electrosurgery system used in a procedure called LETZ(R), tools used in other
minimally invasive surgical procedures including diagnostic laparoscopies, and a
device for the conservative treatment of urinary incontinence.
Critical care product revenues were $2,203,000 (43% of total revenue) in 2Q
1997, compared to $5,148,000 (51% of total revenue) in 2Q 1996. Sales to Baxter
in 2Q 1997 were $393,000 compared to $2,995,000 in 2Q 1996. As previously
announced, Baxter stopped purchasing disposable pressure transducers ("DPT")
from UM at the end of 1996. During the first half (1H) of 1997, total critical
care sales were $4,244,000 compared with $10,938,000 in 1H 1996. Sales to
Baxter were $847,000 in 1H 1997, compared to $6,789,000 in 1H 1996. First half
1997 Baxter sales were non-pressure transducer components.
Critical care blood pressure monitoring is a mature business dominated by
two large suppliers, Baxter and Abbott. UM's non-Baxter critical care sales
were $1,810,000 in 2Q 1997 compared to $2,153,000 in 2Q 1996, but up from
$1,588,000 in 1Q 1997. First Half 1997 non-Baxter critical care sales were
$3,398,000 compared to $4,149,000 in the same period of 1996.
The obstetrics revenue category declined 48.4% in 2Q 1997 from the same
quarter of 1996 and represented 41% of total sales compared to 40% in 1996.
Sales of obstetrics products in 2Q 1997 were $2,091,000 compared to $4,051,000
in 2Q 1996. First half 1997 obstetrics sales were $4,426,000 compared to
$7,497,00 in 1H 1996. In 2Q 1997, UM bought back $643,000 in obstetrics
products from a dealer terminated at the beginning of 1997, and experienced
lower Intran sales compared to 2Q 1996, due to the competitive situation.
Absent the buy-back, obstetric revenues grew 17% from 1Q of this year. UM has
been converting, for the past five years, its Ob/Gyn sales resources in the U.S.
from third party distributors to its own employed direct representatives, and
expects that the changes made at the start of this year will benefit the company
for the rest of 1997 and into the future.
Starting in late July 1997, UM has begun shipping the first of its six new
Intran models offering a smaller tip size and a zero switch located on the
connector cable, along with an amnioinfusion viewport introduced in late 1996.
These new product offerings should allow the state of art Intran Plus catheter
to satisfy customer preferences identified by recent surveys.
The third product line, gynecology products, includes Liberty(R), a system
for conservatively treating urinary incontinence, Lumin(R), a unique tool used
in laparoscopic procedures to manipulate the uterus, and EpitomeTM, a unique
ceramic scalpel, in addition to UM's LETZ system of electrosurgery equipment and
disposable electrodes. Gynecology revenues were $807,000 in 2Q 1997 compared to
$890,000 in 2Q 1996, and represented 16% of total revenues. First half 1997
gynecology revenues were $1,604,000 approximately equal to $1,622,000 in the
same period of 1996, despite being negatively impacted in 1997 by the
distributor change. UM's past successes with its gynecology products resulted
from providing physician training along with equipment and tools designed for
specific procedures. The Company believes that future success will depend on
similar efforts.
The Columbia Medical acquisition announced July 21, 1997 (see note 6 on page
5, above) should provide immediate growth opportunities for UM. CMI's principal
products, vacuum-assisted obstetrical delivery systems are well suited to UM's
current sales focus. Other advantages include the addition of a patented
urology product, bundling help in defending UM's OB business in group contract
bids, and further growth opportunities for sales overseas.
Second quarter and first half 1997 foreign sales were $1,340,000 and
$2,535,000, respectively, compared to $2,601,000 and $5,350,000, respectively,
in the same periods of 1996 (around 25% of total sales in all periods). Lower
sales to Baxter accounted for about 98% of the decrease in 2Q 1997 from 2Q 1996,
and about 93% of the decrease in 1H 1997 from 1H 1996. Critical care products
represented 86% and 85% of international sales in 2Q and 1H 1997, respectively,
compared to 92% in both 2Q and 1H 1996.
UM believes it has substantial sales potential for its products in
international markets, including those acquired in July 1997 through the CMI
purchase, and therefore plans to continue to commit resources to international
business expansion.
c) Gross Profit
Gross margins (profit after subtracting costs of manufacturing products from
revenues) in both 2Q and 1H 1997, were 52.4% compared to 49.6% and 47.9% in 2Q
and 1H 1996, respectively The improvement was achieved because of the
percentage increase in sales of Ob/Gyn products from 49.0% and 45.5% of total
sales in 2Q and 1H 1996, respectively, to 56.8% and 58.7% of sales in 2Q and 1H
1997, respectively, combined with a sharp decrease in Baxter sales, which were
among the Company's least profitable. A primary short-term challenge for UM is
absorption of manufacturing overhead given the current sales volumes and
depreciation related to recent increases in fixed assets. To the extent UM is
successful in growing obstetrics and gynecology revenues, and in switching
distribution channels from distributors to direct representatives, the Company
foresees continued gross margin improvements.
d) Income from Operations
Operating profit, or income from operations, is the profit achieved after
subtracting operating expenses from gross profit. Operating expenses are
subdivided into sales, general and administrative (SG&A) expenses and research
and development (R&D) expenses. UM further divides SG&A into the two categories
of sales and marketing (S&M) expenses and general and administrative (G&A)
expenses.
As a percentage of sales, operating expenses increased to 31.1% in 2Q 1997
compared to 18.8% in 2Q 1996, despite a decrease of $312,000 in operating
expense dollars. Comparing 1H 1997 to the same period of 1996, operating
expenses increased to 31.2% of sales from 18.5% of sales. Second quarter 1997
SG&A expenses decreased 12% from the amounts spent in 1996, but, as a percentage
of sales, increased to 26.2% of sales in 2Q 1997 from 15.1% of sales in 1996.
First half 1997 selling, general and administrative expenses increased to 26.4%
of sales compared to 14.8% in 1H 1996, while declining $258,000 in actual
dollars.
S&M expenses pertain primarily to the "direct sales" portion of UM's
business. In 1997, the S&M expense ratio is expected to remain above historical
levels for two reasons: 1) the decline in Baxter business will continue, on a
relative basis to 1996, to reduce total sales; and 2) the termination of two
additional U.S. distributors at the beginning of the year in favor of adding
directly employed sales representatives will increase incremental sales
expenses.
R&D expenses in 2Q and 1H 1997 were 5.0% and 4.8% of sales, respectively,
compared to 3.8% and 3.7% of sales in 2Q and 1H 1996, respectively. Some R&D
expenses are external costs relating to both process and product validations,
which costs can vary from period to period. The Company employs specialist R&D
resources not only to internally develop its own new product ideas, but also,
through joint development agreements, licensing of technology, acquisitions and
other arrangements, to enhance and complete the commercialization of projects
initiated by others. For example, UM recently announced that it would work in
cooperation with Mayo Clinic to develop and commercialize an advanced
endometrial tissue sampling approach designed by R. Stuart Fowler, M.D., Mayo
Clinic Scottsdale, Arizona. The advancement allowed by this endometrial
sampling invention is a uterine curetting device with the capability of
obtaining a sampling of the endometrial lining that rivals the thoroughness of a
D&C procedure, without cervical dilatation, performed in an office setting.
Second quarter 1997 income from operations was $1,083,098 compared to
$3,104,852 in 2Q 1996. Second quarter 1997 operating margins were 21.2%
compared to 30.8% for the same quarter in 1996. First half 1997 income from
operations declined to 21.2% of sales from 29.4% in 1H 1996.
e) Non-operating Income
Non-operating income includes primarily royalties from licensing UM's
technology to other companies, interest and capital gains from investing the
Company's cash, and gains or losses from the sale of assets. Non-operating
income increased $48,000 to $293,000 in 2Q 1997 from $245,000 in 2Q 1996. For
the first half, non-operating income declined from $1,344,000 in 1996 to
$822,000 in 1997. An extraordinary payment for the use of UM's pressure
monitoring technology in 1Q 1996 is principally responsible for the difference.
Royalties from other medical device companies continue to make a substantial
contribution to non-operating income. Non-operating income during the remainder
of 1997 is expected to be lower than during the same period of 1996 due to
required interest payments on UM's credit line and lower cash balances
generating less investment income, while royalties are expected to be similar in
magnitude to the last half of 1996.
f) Net Income and EPS
Despite lower sales in 2Q and 1H 1997, UM's net income expressed as a
percentage of sales continues at a solid 18% and 19%, respectively, compared to
22% and 23% in 2Q and 1H 1996, respectively. After income taxes, 2Q 1997 net
income was $895,385, compared to $2,170,856 in 2Q 1996. For the first half,
1997 net income was $1,935,370 compared to $4,654,391 in 1996. The effective
income tax rates were between 35% and 36% for all periods.
Earnings per share (EPS) is net income divided by the number of shares of
stock outstanding (fully-diluted to take effect for stock options awarded which
have exercise prices below the current market value). Fully diluted 2Q 1997 EPS
were down 53.6% to $.11 compared to $.23 in 2Q 1996. Second quarter 1997 ending
weighted average number of common shares assuming full dilution (the number used
to calculate EPS) were 8,504,429 shares compared to 9,559,673 in 2Q 1996. The
dilution calculation added about 35,000 shares to weighted actual shares
outstanding in 2Q 1997, compared to about 194,000 for 2Q 1996, due to quarter
ending share prices of $8.19 in 2Q 1997 compared to $12.63 in 2Q 1997. Actual
outstanding common shares as of June 30, 1997 were 8,388,786.
g) Cash Flows
Cash and investments balances were $2.6 million at the end of 2Q 1997, a
decrease of $1.9 million from December 31, 1996. The decrease was due primarily
to the use of $4.3 million for share repurchases. Cash provided by operating
activities, including adjustments for depreciation and other non-cash operating
expenses, along with changes in working capital, totaled $1,401,652 in 1H 1997,
from $5,304,938 in 1H 1996. Apart from net income, which accounted for about
70% of the decrease, a relative increase of $908,000 in inventories was
responsible for a major portion of the decline compared to 1H 1996. Raw
materials inventories have grown in 1997 because of volume purchase commitments
with vendors and the time required to make changes in purchase patterns. As of
June 30, 1997, net accounts receivable balances were $3.1 million which equates
to 55 days sales in receivables (based on 2Q sales), compared to end-of-year
accounts receivable of $3.8 million which equates to 45 days in receivables.
Inventory balances are $1,639,000 higher than at the end of 1996, with inventory
turns now at 1.6 times based on 2Q cost of sales. Inventory control will be an
area of primary focus for the balance of 1997 as UM seeks to reduce debt and
become more efficient with the use of its assets.
Cash of $902,000 was used for capital expenditures in property and
equipment, with an additional $328,000 used to purchase intangible assets.
Capital expenditures during 1H 1997 were made, primarily, in the automation of
key assembly operations, in new product tooling and equipment, for Midvale
building improvements, and for final payments on the Ireland facility. Net
purchases and sales of investments provided $1,289,000 to 1H 1997 cash.
First half 1997 financing activities used cash of $2,063,000 after
repurchases of shares are netted against sales of shares from option exercises
and proceeds from issuance of short-term debt, compared to $10,810,000 in the
same period of 1996. The Company repurchased its own common stock during 1H
1997 in the amount of $4,322,000, down from $10,981,000 used in 1H 1996. In 1H
1997, the Company received $109,000 from issuing stock (on exercise of employee
options), compared to $172,000 in 1H 1996. The Company did not enter into any
long-term debt agreements during the first half of 1997, but opened a $10
million unsecured line of credit in early April 1997, and had net borrowings of
$2,150,000 at June 30 (see below).
Management believes that current cash balances , the credit line, plus
future income from operations will provide the liquidity needed to finance
internal growth plans. In addition to the capital expenditures, UM plans to use
cash during the remainder of 1997 for selective infusions of technological,
marketing or product manufacturing rights to broaden the Company's product
offerings and to reduce credit line balances.
Other
On April 4, 1997, the Company signed a revolving promissory note with its
bank. Under the note, the Company may borrow up to $10,000,000 at a floating
interest rate tied to LIBOR or the Prime Rate at UM's election. Amounts
borrowed under the note are unsecured and are due March 25, 1999. At August 10,
1997, the Company had borrowed approximately $8,000,000 under the note at a
current rate of approximately 7.08% per annum.
PART II - OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
On May 16, 1997, at the annual meeting, shareholders of the Company approved
the following matter submitted to them for consideration:
Elected Kevin L. Cornwell and Perry L. Lane as directors of the Company.
Kevin L. Cornwell: For 7,285,870
Perry L. Lane: For 7,326,410
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
a) Exhibits:
SEC
Exhibit # Reference # Title of Document
1 27 Financial data schedule
b) Reports on Form 8-K:
During the quarter ended June 30, 1997, the Company filed no reports on
Form 8-K.
Subsequent to June 30, on August 4, 1997, UM filed a report on Form 8-K,
Item 2, Acquisition or Disposition of Assets, related to the purchase of
Columbia Medical & Surgical, Inc. (see note 6 on page 5, above). Financial
Statements under Item 7 will be filed by amendment as soon as practicable,
but no later than October 3, 1997.
On August 7, 1997, UM filed a report on Form 8-K/A, Item 7, Exhibits,
related to the Columbia Medical Acquisition.
SIGNATURES
Pursuant to the requirements of the Securities Exchanges Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
UTAH MEDICAL PRODUCTS, INC.
REGISTRANT
Date: 8/13/97 By: /s/ Kevin L. Cornwell
Kevin L. Cornwell
CEO and CFO